ATE522201T1 - Nukleinsäurekomplex und nukleinsäure-abgabe- zusammensetzung - Google Patents
Nukleinsäurekomplex und nukleinsäure-abgabe- zusammensetzungInfo
- Publication number
- ATE522201T1 ATE522201T1 AT08848047T AT08848047T ATE522201T1 AT E522201 T1 ATE522201 T1 AT E522201T1 AT 08848047 T AT08848047 T AT 08848047T AT 08848047 T AT08848047 T AT 08848047T AT E522201 T1 ATE522201 T1 AT E522201T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- delivery composition
- complex
- acid complex
- acid delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Wood Science & Technology (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007291317 | 2007-11-08 | ||
| PCT/JP2008/070642 WO2009061003A2 (en) | 2007-11-08 | 2008-11-06 | Nucleic acid complex and nucleic acid delivery composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE522201T1 true ATE522201T1 (de) | 2011-09-15 |
Family
ID=40303461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08848047T ATE522201T1 (de) | 2007-11-08 | 2008-11-06 | Nukleinsäurekomplex und nukleinsäure-abgabe- zusammensetzung |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8338584B2 (de) |
| EP (1) | EP2217208B1 (de) |
| JP (1) | JP5340282B2 (de) |
| KR (1) | KR101567108B1 (de) |
| CN (1) | CN101854918B (de) |
| AR (1) | AR069224A1 (de) |
| AT (1) | ATE522201T1 (de) |
| AU (1) | AU2008325504B2 (de) |
| BR (1) | BRPI0819187A2 (de) |
| CA (1) | CA2704236C (de) |
| CO (1) | CO6280469A2 (de) |
| CY (1) | CY1112029T1 (de) |
| DK (1) | DK2217208T3 (de) |
| ES (1) | ES2369869T3 (de) |
| HK (1) | HK1142278A1 (de) |
| HR (1) | HRP20110698T1 (de) |
| IL (1) | IL205237A0 (de) |
| MX (1) | MX2010005094A (de) |
| MY (1) | MY149917A (de) |
| NZ (1) | NZ584841A (de) |
| PL (1) | PL2217208T3 (de) |
| PT (1) | PT2217208E (de) |
| RU (1) | RU2465009C2 (de) |
| SI (1) | SI2217208T1 (de) |
| TW (1) | TWI426922B (de) |
| UA (1) | UA97559C2 (de) |
| WO (1) | WO2009061003A2 (de) |
| ZA (1) | ZA201002845B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI428135B (zh) * | 2007-03-26 | 2014-03-01 | Hirofumi Takeuchi | And a carrier composition for quick-acting nucleic acid delivery |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| ES2605990T3 (es) * | 2010-12-29 | 2017-03-17 | F. Hoffmann-La Roche Ag | Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos |
| PL2825565T3 (pl) * | 2012-03-15 | 2019-10-31 | Acraf | Kationowe polimery na bazie glikogenu |
| JPWO2019131727A1 (ja) * | 2017-12-27 | 2021-02-12 | コニカミノルタ株式会社 | 医薬の評価方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01238537A (ja) | 1988-03-18 | 1989-09-22 | Toyo Jozo Co Ltd | 肝障害治療剤 |
| JP3150266B2 (ja) * | 1994-04-01 | 2001-03-26 | 江崎グリコ株式会社 | 環状構造を有するグルカンおよびその製造方法 |
| JP3107358B2 (ja) * | 1994-09-13 | 2000-11-06 | 江崎グリコ株式会社 | 環状構造を有するグルカンおよびその製造方法 |
| US6248566B1 (en) * | 1994-09-13 | 2001-06-19 | Ezaki Glico Co., Ltd. | Glucan having cyclic structure and method for producing the same |
| US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5827697A (en) * | 1995-03-31 | 1998-10-27 | Ezaki Glico Co., Ltd. | Process for preparing glucans having a cyclic structure |
| US20030092180A1 (en) | 2001-08-27 | 2003-05-15 | David Lewis | Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo |
| JPH11292795A (ja) | 1998-04-02 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | Ｈｉｖコファクター抑制剤 |
| US7166745B1 (en) | 1998-11-12 | 2007-01-23 | Invitrogen Corporation | Transfection reagents |
| JP2005527639A (ja) * | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Ｒｎａ干渉の治療的利用のための方法及び組成物 |
| RU2289585C2 (ru) * | 2002-02-04 | 2006-12-20 | Корикса Корпорейшн | Новые аминоалкилглюкозаминидфосфатные соединения, иммуностимулирующая фармацевтическая композиция, их содержащая, и способ индуцирования иммунного ответа |
| US20040204420A1 (en) * | 2002-08-05 | 2004-10-14 | Rana Tariq M. | Compounds for modulating RNA interference |
| US20060030578A1 (en) * | 2002-08-20 | 2006-02-09 | Neopharm, Inc. | Pharmaceutically active lipid based formulation of irinotecan |
| US7780873B2 (en) * | 2004-02-23 | 2010-08-24 | Texas A&M University System | Bioactive complexes compositions and methods of use thereof |
| US20060228420A1 (en) * | 2005-03-15 | 2006-10-12 | Queen Mary & Westfield College | Pharmaceutical compositions comprising microparticles for delivery into neurons |
-
2008
- 2008-06-11 UA UAA201007049A patent/UA97559C2/uk unknown
- 2008-11-05 TW TW097142679A patent/TWI426922B/zh not_active IP Right Cessation
- 2008-11-06 MX MX2010005094A patent/MX2010005094A/es active IP Right Grant
- 2008-11-06 BR BRPI0819187 patent/BRPI0819187A2/pt not_active IP Right Cessation
- 2008-11-06 CN CN2008801151656A patent/CN101854918B/zh not_active Expired - Fee Related
- 2008-11-06 MY MYPI2010001775A patent/MY149917A/en unknown
- 2008-11-06 AT AT08848047T patent/ATE522201T1/de active
- 2008-11-06 RU RU2010123168/15A patent/RU2465009C2/ru not_active IP Right Cessation
- 2008-11-06 ES ES08848047T patent/ES2369869T3/es active Active
- 2008-11-06 PT PT08848047T patent/PT2217208E/pt unknown
- 2008-11-06 PL PL08848047T patent/PL2217208T3/pl unknown
- 2008-11-06 SI SI200830383T patent/SI2217208T1/sl unknown
- 2008-11-06 KR KR1020107012581A patent/KR101567108B1/ko not_active IP Right Cessation
- 2008-11-06 NZ NZ584841A patent/NZ584841A/en not_active IP Right Cessation
- 2008-11-06 EP EP08848047A patent/EP2217208B1/de active Active
- 2008-11-06 DK DK08848047.0T patent/DK2217208T3/da active
- 2008-11-06 JP JP2010517212A patent/JP5340282B2/ja not_active Expired - Fee Related
- 2008-11-06 US US12/741,457 patent/US8338584B2/en active Active
- 2008-11-06 AU AU2008325504A patent/AU2008325504B2/en not_active Ceased
- 2008-11-06 WO PCT/JP2008/070642 patent/WO2009061003A2/en active Application Filing
- 2008-11-06 CA CA2704236A patent/CA2704236C/en not_active Expired - Fee Related
- 2008-11-07 AR ARP080104877A patent/AR069224A1/es unknown
-
2010
- 2010-04-22 ZA ZA2010/02845A patent/ZA201002845B/en unknown
- 2010-04-22 IL IL205237A patent/IL205237A0/en unknown
- 2010-06-08 CO CO10068754A patent/CO6280469A2/es active IP Right Grant
- 2010-09-17 HK HK10108878.8A patent/HK1142278A1/xx not_active IP Right Cessation
-
2011
- 2011-09-29 HR HR20110698T patent/HRP20110698T1/hr unknown
- 2011-11-14 CY CY20111101091T patent/CY1112029T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| LTC2140867I2 (lt) | Farmacinė kompozicija | |
| BRPI0721651A2 (pt) | Composição farmacêutica | |
| BRPI0819573A2 (pt) | Composição e artigo | |
| BRPI0715712A2 (pt) | Composição farmacêutica | |
| BRPI0716300A2 (pt) | Artigo e mistura | |
| BRPI0906962A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0906556A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0719393A2 (pt) | Composição farmacêutica | |
| DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
| ATE526567T1 (de) | Zusammensteller und zusammenstellungsverfahren | |
| DK2120884T3 (da) | Farmaceutisk sammensætning | |
| ATE510923T1 (de) | Nukleinsäure | |
| BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
| DK2285413T3 (da) | Farmaceutisk sammensætning | |
| BRPI0905715A2 (pt) | Composição farmacêutica e kit de componentes | |
| BRPI0720234A2 (pt) | Composição farmacêutica | |
| BRPI0917681A2 (pt) | Composto, e, composição farmacêutica | |
| BRPI0921313A2 (pt) | composição farmaucêutica | |
| BRPI0817833A2 (pt) | Composição farmacêutica antimalárica | |
| BRPI0820198A2 (pt) | composições farmacêuticas | |
| BRPI0912171A2 (pt) | composição farmacêutica | |
| BRPI0914182A2 (pt) | composto, e, composição farmacêutica | |
| ATE522201T1 (de) | Nukleinsäurekomplex und nukleinsäure-abgabe- zusammensetzung | |
| BRPI0912074A2 (pt) | composto e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2217208 Country of ref document: EP |